Generic competition cuts Merck's Q1 sales, profit

May 1, 2013

Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

Merck's first-quarter profit fell 8.3 percent and revenue by 9 percent, mainly because competition from generics slashed sales of its top seller, asthma and allergy drug Singulair.

The Whitehouse Station, N.J. company says net income was $1.59 billion, or 52 cents per share, down from $1.74 billion, or 56 cents per share, a year earlier.

Adjusted earnings were 85 cents per share, a nickel more than analysts expected.

Revenue totaled $10.67 billion, down from $11.73 billion. Analysts expected $11.11 billion.

shares fell 99 cents to $46.01 in premarket trading.

Explore further: Merck's 2Q net falls on charges, but sales rise

Related Stories

Merck's 2Q net falls on charges, but sales rise

July 27, 2012

Merck & Co.'s second-quarter net income fell 11.4 percent as slightly higher sales were offset by acquisition and restructuring costs. However, the drugmaker beat Wall Street expectations, and Merck shares jumped in early ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.